Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

120

total

757.123

impact factor

6.309

average impact factor

Director: Juan Angel Recio Conde

team

zoom

download

The research interest of the group is focused on the molecular basis of skin cancer progression and resistance to treatment. We investigate the molecular causes for these diseases in order to design effective therapies against them. This is done in close proximity to patients where our goal is to translate our discoveries as fast as possible to patients. In this matter we have recently contributed to design novel melanoma therapeutic approaches targeting cancer metabolism (Oncogene. 2017 Oct 12;36(41):5695-5708) These investigations have been continuously funded by the industry and the 7^th Framework Programme European Union, Marie Curie Actions. As a result of these investigations is planned to perform a phase I, IIa and IIb clinical trial. In addition to this, we have described for the first time the genetic alterations associated to the malignant squamous cell carcinomas developed in Epidermolysis Bullosa (RDEB-SCC), a genetic rare disease associated to germinal mutations, contributing to better understand these tumors.

5

total

23^.742

impact factor

4^.748

average impact factor

SELECTED ARTICLES

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.
Pérez-Alea M, McGrail K, Sánchez-Redondo S, Ferrer B, Fournet G, Cortés J, Muñoz E, Hernandez-Losa J, Tenbaum S, Martin G, Costello R, Ceylan I, Garcia-Patos V, Recio JA.
Oncogene. 2017 Oct 12;36(41):5695-5708.
doi: 10.1038/onc.2017.160.
Epub 2017 Jun 5.
IF: 7.52
Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression.
Sans-DeSanNicolas L, Caratú G, Vidal-Cortés O, Sanchez-Redondo S, Ferrer B, Mancuso F, González-Sanchez E, Pérez-Alea M, McGrail K, Hernandez-Losa J, Bodet D, Vivancos A, Garcia-Patos V, Recio JA.
J Invest Dermatol. 2018 Jun;138(6):1423-1427.
doi: 10.1016/j.jid.2017.12.026.
Epub 2017 Dec 29.
IF: 6.29
Utility of Ultrasound in a Rapidly Growing Cutaneous Nodule in an Infant.
Ubals M, Castany A, Bassas P, Mollet J, Aparicio G, García-Patos V.
J Pediatr. 2017 Jan;180:290-290.e1.
doi: 10.1016/j.jpeds.2016.09.038.
Epub 2016 Oct 14.
IF:3.87
Use of Molecular Biology Techniques in Sarcoidal Granulomatous Dermatitis: A Clinicopathological and Molecular Approach with Diagnostic Implications.
Esteves TC, Tórtola T, Ferrer B, Aparicio G, Sulleiro E, González-López J, Moure Z, Romero D, Garcia-Patos V.
Acta Derm Venereol.
2017 Nov 15;97(10):1241-1242.
doi: 10.2340/00015555-2745.
IF: 3.65
Spiny hyperkeratosis (trichodysplasia spinulosa-like eruption): a cutaneous adverse effect of Hedgehog pathway inhibitors involving expression of p16.
López-Lerma I, Ferrer B, Zarzoso I, Hernández-Losa J, García-Patos V.
J Eur Acad Dermatol Venereol. 2017 Apr;31(4):e182-e184. doi: 10.1111/jdv.13907.
IF: 3.53

Oncology

Overview

Publications

Director: Juan Angel Recio Conde

Research Areas